Previous 10 | Next 10 |
home / stock / abscf / abscf news
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE EUROPEAN MEDICINES AGENCY'S TIMETABLE FOR EXAMINATION OF THE MARKETING AUTHORIZATION APPLICATION OF MASITINIB IN AMYOT RO PHIC LATERAL SCLEROSIS BASED ON THE UPDATED TIMETABLE, A...
PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERING MASITINIB IN THE TREATMENT OF METASTATIC CASTRATE REFRACTORY PROSTATE CANCER ( mCRPC ) , STRENGTHENING THE COMPANY’S INTELLECTUAL PROPERTY POSITION...
PRESS RELEASE AB SCIENCE ANNOUNCES ISSUANCE OF A CANADIAN PATENT FOR MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) WITH PROTECTION UNTIL 203 7 CANADIAN PATENT COMPLETES INTELLECTUAL PROPERTY COVERAGE F OR ALS ACRO...
PRESS RELEASE AB SCIENCE SUMMARIZES KEY MESSAGES FROM ITS PARTICIPATION TO A PANEL DISCUSSION AT THE 202 3 ALS DRUG DEVELOPMENT SUMMIT (BOSTON, USA) Paris, 17 May , 202 3 , 8 :00 pm CET AB Scie...
PRESS RELEASE AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS RESUMED ITS REVIEW OF THE NEW DRUG SUBMISSION FOR MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS , FOLLOWING ISSUANCE OF A SCREENING ACCEPTANCE LETTER Paris, 09 May , ...
PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 202 2 AND THE KEY EVENTS OF THE PERIOD Financial information and other corporate information Consolidated operating loss of €15.9 million as of 31 December 2022, c...
PRESS RELEASE AB SCIENCE SUMMARIZES THE PRESENTATION ON MASITTINIB IN AMYOTROPHIC LATERAL SCLEROSIS MADE A T THE AMERICAN ACADEMY OF NEUROLOGY 2023 ANNUAL MEETING , INCLUDING LONG-TERM SURVIVAL ANALYS IS AND NEW ANALYSIS OF PATIENT POPULATION WITH NO COMPLETE L...
PRESS RELEASE AB SCIENCE ANNOUNCES MASITINIB PATENT GRANTED IN JAPAN FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS, S TRENGTHENING THE COMPANY’S INTELLECTUAL PROPERTY POSITION UNTIL 203 7 TO DATE , THIS PATENT HAS BEEN GRANTED IN ...
PRESS RELEASE RESULTS OF MASITINIB IN ALS SELECTED FOR A SCIENTIFIC PLATFORM PRESENTATION AT THE AMERICAN ACADEMY OF NEUROLOGY 2023 ANNUAL MEETING , INCLUDING LONG-TERM SURVIVAL ANALYS IS AND NEW ANALYSIS OF PATIENT POPULATION WITH NO COMPLETE LOSS OF F...
PRESS RELEASE AB SCIENCE ANNOUNCES THAT IT HAS SUBMITTED ITS RESPONSE TO THE DAY 120 QUESTIONS IN THE EMA REGULATORY REVIEW OF MASITINIB IN AMYO TROPHIC LATERAL SCLEROSIS AND CLARIFIES THE NEW TIMELINE FOR RESPONDING TO HEALTH CANADA Paris, A pril ...
News, Short Squeeze, Breakout and More Instantly...
Ab Science Paris Ord Company Name:
ABSCF Stock Symbol:
OTCMKTS Market:
PRESS RELEASE AB SCIENCE REPORTS POSTIVE RESULTS OF ITS PHASE 2 STUDY EVALUATING MASITINIB IN COVID-19 Paris, 8 July 2024, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announces the results of a Phase 2 study evaluating masitinib in COVID-19. This rando...
PRESS RELEASE SUMMARY OF THE WEBCAST HELD ON MAY 30, 2024, PROVIDING AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Paris, May 31, 2024, 4.30pm CET AB Science SA (Euronext - FR0010557264...
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Paris, 29 May, 2024, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces that the Commit...